The use of the anti-malaria drug Fansidar® (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency

24Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Fas is a protein that plays a major role in the apoptotic mechanism of several cell types, including white blood cells (WBC). Mutations of the Fas gene in humans are known to lead to autoimmune lymphoproliferative syndrome (ALPS). Glucocorticoids or cytostatic drugs are sometimes used to treat the lymphoproliferation in these patients. When treated with the anti-malaria drug Fansidar®, a patient with ALPS showed a marked shrinkage of the lymph node masses, decrease in peripheral blood lymphocytes (PBL) and an increase in neutrophil numbers. In addition, an increased Fas expression was seen on all types of leucocytes.

Cite

CITATION STYLE

APA

Van Der Werff Ten Bosch, J. E., Demanet, C., Balduck, N., Bakkus, M. H. C., De Raeve, H., Desprechins, B., … Thielemans, K. (1998). The use of the anti-malaria drug Fansidar® (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency. British Journal of Haematology, 102(2), 578–581. https://doi.org/10.1046/j.1365-2141.1998.00791.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free